# 3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

> **NCT02034773** · PHASE1 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 64 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** CC-220
- **DRUG:** CC-220
- **DRUG:** CC-220
- **DRUG:** CC-220
- **DRUG:** Placebo
- **DRUG:** CC-220
- **DRUG:** CC-220
- **DRUG:** CC-220

## Key facts

- **NCT ID:** NCT02034773
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2014-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02034773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02034773, "3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02034773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*